The epidermal growth factor receptor (EGRF) in lung cancer

In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovere...

Descripción completa

Detalles Bibliográficos
Autores principales: Carcereny, Enric, Morán, Teresa, Capdevila, Laia, Cros, Sara, Vilà, Laia, de los Llanos Gil, Maria, Remón, Jordi, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366432/
https://www.ncbi.nlm.nih.gov/pubmed/25810955
http://dx.doi.org/10.1186/s40247-015-0013-z
_version_ 1782362366541824000
author Carcereny, Enric
Morán, Teresa
Capdevila, Laia
Cros, Sara
Vilà, Laia
de los Llanos Gil, Maria
Remón, Jordi
Rosell, Rafael
author_facet Carcereny, Enric
Morán, Teresa
Capdevila, Laia
Cros, Sara
Vilà, Laia
de los Llanos Gil, Maria
Remón, Jordi
Rosell, Rafael
author_sort Carcereny, Enric
collection PubMed
description In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.
format Online
Article
Text
id pubmed-4366432
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-43664322015-03-25 The epidermal growth factor receptor (EGRF) in lung cancer Carcereny, Enric Morán, Teresa Capdevila, Laia Cros, Sara Vilà, Laia de los Llanos Gil, Maria Remón, Jordi Rosell, Rafael Transl Respir Med Review In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer. Springer Berlin Heidelberg 2015-02-24 /pmc/articles/PMC4366432/ /pubmed/25810955 http://dx.doi.org/10.1186/s40247-015-0013-z Text en © Carcereny et al.; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Review
Carcereny, Enric
Morán, Teresa
Capdevila, Laia
Cros, Sara
Vilà, Laia
de los Llanos Gil, Maria
Remón, Jordi
Rosell, Rafael
The epidermal growth factor receptor (EGRF) in lung cancer
title The epidermal growth factor receptor (EGRF) in lung cancer
title_full The epidermal growth factor receptor (EGRF) in lung cancer
title_fullStr The epidermal growth factor receptor (EGRF) in lung cancer
title_full_unstemmed The epidermal growth factor receptor (EGRF) in lung cancer
title_short The epidermal growth factor receptor (EGRF) in lung cancer
title_sort epidermal growth factor receptor (egrf) in lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366432/
https://www.ncbi.nlm.nih.gov/pubmed/25810955
http://dx.doi.org/10.1186/s40247-015-0013-z
work_keys_str_mv AT carcerenyenric theepidermalgrowthfactorreceptoregrfinlungcancer
AT moranteresa theepidermalgrowthfactorreceptoregrfinlungcancer
AT capdevilalaia theepidermalgrowthfactorreceptoregrfinlungcancer
AT crossara theepidermalgrowthfactorreceptoregrfinlungcancer
AT vilalaia theepidermalgrowthfactorreceptoregrfinlungcancer
AT delosllanosgilmaria theepidermalgrowthfactorreceptoregrfinlungcancer
AT remonjordi theepidermalgrowthfactorreceptoregrfinlungcancer
AT rosellrafael theepidermalgrowthfactorreceptoregrfinlungcancer
AT carcerenyenric epidermalgrowthfactorreceptoregrfinlungcancer
AT moranteresa epidermalgrowthfactorreceptoregrfinlungcancer
AT capdevilalaia epidermalgrowthfactorreceptoregrfinlungcancer
AT crossara epidermalgrowthfactorreceptoregrfinlungcancer
AT vilalaia epidermalgrowthfactorreceptoregrfinlungcancer
AT delosllanosgilmaria epidermalgrowthfactorreceptoregrfinlungcancer
AT remonjordi epidermalgrowthfactorreceptoregrfinlungcancer
AT rosellrafael epidermalgrowthfactorreceptoregrfinlungcancer

Ejemplares similares